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Abstract
Introduction The purpose of this review is to document the
various types of astrocytoma that occur in the fetus and neo-
nate, their locations, initial findings, pathology, and outcome.
Data are presented that show which patients are likely to sur-
vive or benefit from treatment compared with those who are
unlikely to respond.
Materials and methods One hundred one fetal and neonatal
tumors were collected from the literature for study.
Results Macrocephaly and an intracranial mass were the most
common initial findings. Overall, hydrocephalus and intracra-
nial hemorrhage were next. Glioblastoma (GBM) was the
most common neoplasm followed in order by subependymal
giant cell astrocytoma (SEGA), low-grade astrocytoma, ana-
plastic astrocytoma, and desmoplastic infantile astrocytoma
(DIA). Tumors were detected most often toward the end of
the third trimester of pregnancy.
Conclusion A number of patients were considered inoperable
since their tumor occupied much of the intracranial cavity
involving large areas of the brain. High-grade astrocytomas
were more common than low-grade ones in this review.
Fetuses and neonates with astrocytoma have a mixed progno-
sis ranging from as low as 20% (GBM) to a high of 90%. The
overall survival was 47/101 or 46 %.
Keywords Fetal astrocytoma . Neonatal astrocytoma .
Perinatal astrocytoma . Intracranial hemorrhage . Congenital
brain tumor
Introduction
Glial cells are the supportive elements of the central nervous
system (CNS) [22]. They include astrocytes, oligodendro-
cytes, and ependymal cells, and the corresponding tumors
originating from these cells astrocytoma, oligodendroglioma,
and ependymoma all of which are loosely called Bglioma^
[16, 22]. The term Bglioma^ is used interchangeably with
astrocytoma to describe the more common subgroup of tu-
mors [22].
Glioma (astrocytoma) is the leading CNS tumor in chil-
dren. Low-grade gliomas are the leading pediatric CNS tu-
mors overall and are responsible for approximately one third
of cases [22, 63]. Higher grade gliomas occur less often and
account for 7–11 % of cases of CNS malignancy beyond
infancy [22, 28].
Low- and high-grade astrocytoma differs significantly in
terms of their histological grading, site of origin, treatment,
and prognosis. The various types of tumors within the group
of low-grade astrocytoma are classified as WHO grade I and
grade II [13, 39]. Themajor histological subtype in the perinatal
period is the pilocytic astrocytoma, a WHO grade I tumor that
is usually well circumscribed and has only a narrow margin of
infiltration into the surrounding tissues [13]. Next in frequency
is the fibrillary astrocytoma (WHO grade II), which has a ten-
dency to be more infiltrative. High-grade astrocytomas are
those graded III (e.g., anaplastic astrocytoma) or IV (e.g., glio-
blastoma) and comprise approximately 7–11 % of pediatric
tumors [28]. Perinatal strocytomas vary from benign (low-
grade) to malignant (high-grade) tumors [9, 18, 30, 32, 49,
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51, 63, 69]. High-grade astrocytomas were more prevalent than
low-grade ones in this review, 55 versus 46 % (Table 9).
Fetal and neonatal brain tumors are rare comprising only
0.5–1.5 % of all childhood CNS tumors [68]. Astrocytoma is
not only the main neuroglial tumor but also second in inci-
dence following intracranial teratoma [12, 24, 30–32, 35, 36,
55, 76, 82, 90]. Perinatal astrocytomas occur most often out-
side the posterior cranial fossa and above the tentorium.
Cerebral hemisphere is the main location where they tend to
be large, involve more than one lobe, and displace the lateral
and/or third ventricles [24, 30, 35, 36, 55, 56, 81, 82].
Intracranial mass, macrocephaly, hydrocephalus, and hemor-
rhage are the most common initial imaging findings [23, 27,
30, 32, 38, 51] (Tables 2, 3, 4, 5, 6, 7, and 8). However, the
leading presentation is an intracranial mass detected on rou-
tine prenatal sonograms [23, 27, 30, 32, 81]. Differential di-
agnosis of a brain tumor includes vascular malformation, in-
farction, or hemorrhage [21, 47, 83, 84].
Materials and methods
Retrospective review of 101 cases including 57 fetuses and 44
neonates with astrocytoma was performed. They were collect-
ed from the literature, mostly from the archives of the National
Library of Medicine (PubMed MEDLINE) and from our in-
stitution. The study was confined to fetuses with astrocytoma
that were detected prenatally by imaging studies or discovered
at birth and neonates with tumors occurring during the first
2 months of life. Only patients with adequate clinical and
pathological data and where outcomes of pregnancy and sur-
vival were given were accepted for review. The following data
were collected and tabulated: maternal age, gravida, initial
presentation, and obstetric management, and the fetal data—
sex of the fetus, weeks of gestation, birth weight, tumor loca-
tion and dimensions, histology and grade, treatment, and out-
come. Diagnosis of the various tumors was established in
patients included in the study by histological confirmation of
biopsy or surgical and/or postmortem specimens. Time period
of patient accrual was from 1970 to 2015. Length of follow-up
varied from 1 week to 1 year.
Results
One hundred one fetuses and neonates, presented with astro-
cytoma (Tables 1, 2, 3, 4, 5, 6, 7, 8, and 9). Most tumors were
detected during the third trimester of pregnancy. They varied
from low-grade, I and II, to high-grade malignancies (grades
III and IV) (Tables 2, 3, 4, 5, 6, 7, and 8). High-grade astro-
cytomas were more prevalent than lower grade ones, a ratio of
1.5:1. Glioblastoma was the major neoplasm, 45 or 44.6 %.
Next were subependymal giant cell astrocytoma 18 (17.9 %),
followed by ten examples of each anaplastic astrocytoma
(9.9 %), low-grade (I–II) astrocytoma (9.9 %), and
desmoplastic infantile astrocytoma/ganglioglioma (9.9 %);
the two less common tumors were astroblastoma, 5 (4.9 %),
and gemistocytic astrocytoma, 3 (2.97 %) examples.
Overall, the main presenting findings were macrocephaly
and an intracranial mass followed by hydrocephalus and intra-
cranial hemorrhage (Tables 1, 2, 3, 4, 5, 6, 7, 8, and 9). Nine
percent (5/57) of the affected fetuses were stillborn. The overall
survival for both fetuses and neonates was 47/101 or 46.5 %.
Glioblastoma malignant astrocytoma grade 4 (GBM)
Arises from the cerebral hemispheres and basal nuclei of fe-
tuses, stillbirths, and infants [21, 23, 24, 30, 38, 43, 49, 68, 72].
It is the leading form of astrocytoma in this and in other similar
perinatal studies [12, 15, 30, 31, 68]. GBM comprised almost
half of the cases here (Tables 1, 2, and 9). An echogenic mass
occupying much of one or both hemispheres accompanied by a
shift of midline structures, obstructive hydrocephalus, and hem-
orrhage were the main prenatal ultrasound findings [21, 23, 38,
89, 93] (Table 2). Serial imaging studies showed that tumor
growth developed rapidly over a surprisingly short period of
time. Intracranial hemorrhage contributed also to the tumor’s
rapid size increase [38, 89]. Dystocia occurred when there was
a large space occupying intracranial mass. Cephalocentesis
(cranial perforation) may be required for removal of the tumor
before vaginal delivery could occur [1]. Large head circumfer-
ence, hydrocephalus, and a bulging anterior fontanel were the
main presenting findings in the neonate.
Pathology
The cerebral hemisphere was the most common site of origin,
namely, 34/45 or 76 % (Table 2). On gross inspection, many
GBMs were large with soft pale-gray, hemorrhagic, and ne-
crotic areas [35, 42, 82, 84]. Microscopically, they showed
hypercellularity, marked pleomorphism, tumor giant cells, mi-
crovascular proliferation, and Bpalisading necrosis^
Table 1 Distribution of 101 perinatal astrocytomas
Tumor Number (%)
Glioblastoma 45 (44.6)
Subependymal giant cell astrocytoma 18 (17.9)
Low-grade, I–II, astrocytoma 10 (9.90)
Anaplastic astrocytoma 10 (9.90)
Desmoplastic infantile astrocytoma/ganglioglioma 10 (9.90)
Astroblastoma 5 (4.90)
Gemistocytic astrocytoma 3 (2.97)
Total 101 (100)
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Table 2 Fetal and neonatal glioblastoma (n = 45)
Female/male 21/17 = 1.23a
Fetusesb 28
Neonatesc 17
Gestation (weeks) 36, range 29–40
Birth weight (g) 3152, range 1400–4270
Maternal history
Maternal age (years) 27 years, range 17–38








Intracranial mass on imaging 26
Intracranial hemorrhage 13













Cerebral hemisphere, NOSe 34
Thalamus 3
Cerebellum and cerebellar-pontine angle 2
Cerebellum and basal ganglia 2
Midline suprasellar 1
Hypothalamus 1
Midline replacing most of brain 1
Cerebral hemisphere replaced by tumor 1
Tumor filled intracranial cavity replacing brain 1
Septum pellucidum and adjacent ventricle 1
Tumor characteristics
Brain weight (g) 597, range 250–850
Tumor weight (g) 20, 5.8f
Tumor greatest dimension (cm) 9.6, range 5–11
Treatment
Patients treated 16 (35.6)
Patients not treated 29 (64.4)
Survival with surgical resection alone 2/6
Survival with SR + CTc 4/4
Survival with SR + XRT 2/2
Survival with SR + CT + embolization 1/1
Survival with SR + CT + XRT 0/2
Survival with CT 0/1
Outcome
Fetal survival 2/31 (6.0)
Neonatal survival 7/14 (50)
Patients treated survived 9/16 (56)
Patients not treated survived 0/29
Overall survival 9/45 = 20 %
Cases selected from the literature
CT chemotherapy, NOS not otherwise specified, SR surgical resection,
XRT radiation therapy
a Sex not stated in seven patients
b Tumor discovered prenatally or on the first day of life
c Tumor discovered within the first 2 months of life
d Eye signs: setting sun, doll’s eyes, nystagmus
e Cerebral hemisphere locations: parietal 3, frontal 2, and one each: pari-
etal-occipital, frontal-parietal
f Tumor weights were given only in two patients
g Two of nine survivors were alive with disease
Table 3 Fetal and neonatal subependymal giant cell astrocytoma
(n = 18)
Male/female 14/4 = 3.5
Fetusesa 11
Neonatesb 7
Gestation (weeks) 35, range 22–40
Birth weight (g) 2653, range 2100–3600
Family history of tuberous sclerosis 1
None 9
Family history not stated 8
Maternal history
Maternal age 27 years, range 17–38




Termination of pregnancy 1
Initial findings
Cerebral hemisphere mass 14
Hydrocephalus 11





Subependyma lateral ventricle adjacent
to foramen of Monro
10
Cerebral hemisphere, NOS 4
Subependyma lateral ventricle, basal ganglia,
and/or thalamus
2
Within a lateral ventricle 2
Tumor characteristics
Tumor greatest dimension (cm) 4, range, 2–9
Treatment
Patients treated 12d
Patients not treated 5e
Survival with surgery alone 9/11 (81.8)f
Survival SR + CT 2/2 (100)g
Patients lost to follow-up 1
Outcome
Fetal survival 6/11 (54.5)
Neonatal survival 5/6 (83.3)h
Patients treated survived 11/12 (91.7)
Patients not treated survived 1/6 (16.7)
Overall survivalh 12/17 = 70.6 %
Cases selected from the literature
CT chemotherapy, NOS not otherwise specified, SR surgical resection,
XRT radiation therapy
a Tumor discovered prenatally or on the first day of life
b Tumor discovered within first the 2 months of life
c Other initial findings, one each: fetal hydrops, dystocia, hydramnios,
lethargy, hypotonia, opisthotonus, abnormal eye movements, vomiting,
hemiparesis, cyanosis, respiratory distress
d Patients treated: seven fetuses, five treated
e Patients not treated: four fetuses, five neonates
f ( ) = percent
g SR + CT; one fetus and one neonate
h One neonate was lost to follow-up
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(neoplastic spindle-shaped cells form palisades around central
necrotic foci) [11, 13, 30, 39] (Fig. 1). GFAP and vimentin are
immunoreactive. Some other findings include a strong nuclear
expression of p53 and 10q deletions. High-grade astrocytomas
were more prevalent than low-grade ones in this review.
Fetal and neonatal GBMs are genetically different from
their adult counterparts and show a low frequency of known
genetic defects [11].
Table 4 Fetal and neonatal Blow-grade^ astrocytoma (grades I and II)
(n = 10)
Male/female 6/4 = 1.5
Fetusesa 3
Neonatesb 7
Gestation (weeks) 39, range 37–40








Mass discovered on imaging 8
Intracranial hemorrhage 3
Bulging anterior fontanel 3
Macrocephalus 2















Patients not treated 0
Survival with surgical resection alone 9/9




Patients with spinal cord tumors who
survived with significant disabilities
3/4 (75)
Overall survival 9/10 = 90 %
Cases selected from the literature
CT chemotherapy, SR surgical resection
a Tumor discovered prenatally or on the first day of life
b Tumor discovered within the first 2 months of life
cMaternal age and gravida were given only in one of ten reports
d Other initial findings, one each: hydrocephalus, dystocia, head tilt, sei-
zures, irritability, poor feeding, vomiting
e Optic nerve tumor eye associated signs: microphthalmia, orbital cyst,
proptosis, exophthalmia
f Tumor characteristics such as brain weight, tumor weight, and tumor
dimensions were not listed in the ten reports reviewed
Table 5 Fetal and neonatal anaplastic astrocytoma (n = 10)
Female/male 5/4 = 1.25a
Fetusesb 7
Neonatesc 3
Gestation (weeks) 37, range 31–40
Birth weight (g) 3873, range 3100–4700
Maternal history
Maternal age (years) 28 years, range 20–33




Termination of pregnancy 1
Initial findings









Cerebral hemispheree 10/10 (100)
Tumor characteristics
Tumor greatest dimension (cm) 9 cm, range 6–12
Weightf
Treatment
Patients treated 6/10 (60)
Patients not treated 4/10 (40)
Survival with surgical resection alone 2/2 (100)
Survival with SR + CTf 3/3 (100)
Survival with SR + CT + XRT 1/1 (100)
Outcome
Fetal survival 5/7 (71.4)
Neonatal survival 1/3 (33.3)
Patients treated survived 6/6 (100)
Patients not treated survived 1/1 (100)
Overall survival 6/10 = 60 %g
Cases selected from the literature
CT chemotherapy, SR surgical resection, XRT radiation therapy
a Sex not stated in one patient
b Tumor discovered prenatally or on the first day of life
c Tumor discovered on the first 2 months of life
d Other presenting findings, one each: dystocia, vomiting, palsy,
hemiparesis, no recognizable cerebral structures
e Cerebral hemisphere locations: one each, parietal, parietal-occipital,
temporal, both cerebral hemispheres; cerebral hemisphere site, not spec-
ified, 6
f Tumor weights were given only in four patients
g Three survivors were alive with disease
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Treatment and outcome
Fetuses with GBM may be born moribund or die soon after
birth [1, 21, 27, 30, 49]. The prognosis for young patients
with this tumor is discouraging low (Table 2). The overall
survival rate was only 9 of 45 or 20 % (Tables 2 and 9).
Nevertheless, cure was not always out of the question. All
six patients who had surgical resection and chemotherapy
[10, 11, 46, 50], one with surgical resection, embolization,
and chemotherapy [74], and two of six who received sur-
gery as the only treatment, survived [93] (Table 2).
Neonatal survival of 50 % was higher than fetal, which
was only 6.5 %.
Table 6 Fetal and neonatal desmoplastic infantile astrocytoma/
ganglioglioma (n = 10)
Female/male 5/4 = 1.25a
Fetusesb 1
Neonatesc 9







Intracranial mass on imaging 7










Bilateral cerebral hemispheres 1
Cerebral hemisphere replaced by tumor 1
Tumor characteristics
Tumor greatest dimension (cm) 11.8, range 11–13
Tumor diagnoses
Desmoplastic infantile gangliogliomae 7
Desmoplastic infantile astrocytomaf 3
Treatment
Patients treated 10
Survival with surgical resection alone 8/9 (89)h
Survival with SR + CTg 0/1
Outcome
Fetal survival 1/1
Neonatal survival 7/9 (77.8)
Patients treated survived 8/10 (80)
Overall survival 8/10 = 80 %
Cases selected from the literature
CT chemotherapy, DIG desmoplastic infantile astrocytoma, GBM glio-
blastoma, SR surgical resection
a In one patient sex was not stated
b Tumor discovered prenatally or on the first day of life
c Tumor discovered within the first 2 months of life
d Gravida and maternal age were not mentioned in the ten reports
reviewed
eOther initial findings, one example each: hydrocephalus, vomiting, set-
ting sun eye sign, lethargy, hemiparesis, hypotonia, malaise, intracranial
hemorrhage, breech presentation, dystocia
f Desmoplastic infantile ganglioglioma: ganglion cells present in addition
to astrocytic cells
g Desmoplastic infantile astrocytoma: astrocytic cells present; ganglion
cells not present
h One patient was operated upon at age 2 months for removal of DIG.
Subsequently 8 years later, the tumor recurred as GBM [2]
Table 7 Fetal and neonatal astroblastoma (n = 5)
Male/female 4/1 = 4
Fetusesa 4
Neonatesb 1
Gestation (weeks) 35, range 31–39
















Cerebral hemisphere replaced by tumor 2
Tumor characteristics
Tumor greatest dimension (cm) 10, range 9–11
Treatment
Patients treated 4
Patients not treated 1
Survival with surgical resection alone 0/2
Survival with SR + CT 2/2 (100)
Outcome
Fetal survival 1/3 (33.3)e
Neonatal survival 1/1 (100)
Patients treated survived 2/4 (50)
Patients not treated survived 0/1
Overall survival 2/5 = 40 %
Cases selected from the literature
a Tumor discovered prenatally or on the first day of life
b Tumor discovered within the first 2 months of life
cMaternal age and gravida were given for patient no. 5 (age 29, G4, P3)
d Cerebral hemisphere locations: cerebral hemisphere ( frontal lobe 2,
cerebral hemisphere, site NOS, 3)
e Fetus lost to follow-up (presumed dead)
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Subependymal giant cell astrocytoma (SEGA) is one of the
unique forms of astrocytoma. It occurs in brains of patients
with tuberous sclerosis (TSC) and in those without the dis-
ease. Most are found during the first and second decades of
life and only occasionally in the perinatal period [30, 31, 51,
56, 58–60, 63] (Table 3).
TSC is an autosomal-dominant inherited condition charac-
terized by highly variable clinical manifestations including
seizures, mental retardation, skin lesions, and hamartomas af-
fecting multiple organ systems such as the heart, brain, eye,
and kidney [33, 60, 73, 89] (Table 3). Brain lesions consist of
subependymal nodules, white matter heterotopias, cortical tu-
bers, and SEGA [73]. Cortical tubers and subependymal nod-
ules are much more common than SEGA [31]. Tubers are
situated throughout the white matter whereas subependymal
nodules characteristically are found in or near the ventricles.
The former are composed of firm, focal areas consisting of
large eosinophilic cells with prominent nuclei suggesting fea-
tures of both neurons and astrocytes [13, 33, 73].
Subependymal nodules have a histological appearance similar
to SEGA. In some instances, there is really no well-defined
cytologic difference between the two. Moreover, serial imag-
ing and biopsy studies reveal transitions of subependymal
nodules to SEGA [73]. Apparently, size of the lesion does
not seem to be helpful in distinguishing between the two.
Fetuses and neonates with TSC present more often clini-
cally with their cardiac problems, namely uncontrollable ar-
rhythmias and intracavitary outflow obstruction due to
rhabdomyoma(s), rather than manifestations of their CNS pa-
thology [30, 31, 33, 89]. For example, 11 of 18 fetuses and
neonates in the study here had 1 or more cardiac
rhabdomyoma. Newborns diagnosed initially with SEGA
may go on to develop other manifestations of TSC [33].
Table 3 shows that males are affected more often than fe-
males, a ratio of 3.5 to 1. Of the 18 patients with SEGA a
family history of TSC was given only in one; however, a
history of this disease was not mentioned in eight patients.
Hydrocephalus and an intracranial mass were the main pre-
senting findings (Table 3). SEGAs appeared on sonograms as
subependymal echogenic nodules situated in the walls of lat-
eral ventricles typically near the foramen ofMonro. The tumor
was nodular and of mixed signal or iso-dense to the brain,
enhancing densely with contrast on CT scan. Calcifications
are noted often within the tumor [51, 56, 59, 63].
Pathology
SEGAs occurred as outgrowths from within or beneath the
walls of lateral ventricles. They obstructed the foramen of
Monro or blocked the third ventricle producing hydrocephalus
[30, 51, 56, 58]. Cerebral hemisphere was the most common
site of origin occurring all 18 patients here (Table 3). Ten were
located near or within the foramen of Monro obstructing it.
Microscopic examination reveals large astrocytic cells with
abundant pink staining cytoplasm, slightly vesicular nuclei,
and prominent nucleoli (Fig. 2). Cells are surrounded by nu-
merous fibrillary processes. The tumors are variably




Gestation (weeks) 35, range 32–40
Birth weight (g) 3523c
Maternal history








Intracranial mass discovered on imaging 2
Intracranial hemorrhage 2






Cerebral hemisphere, occipital lobe 1
Cerebral hemispheres replaced by tumor 1
Tumor filled one half of intracranial cavity 1
Tumor characteristics
Brain weight (g) 654c
Tumor weight (g)
Tumor greatest dimension (cm)
Treatment and survival
Patients treated 1 (1/3)
Patients not treated 2 (0/3)
Survival with surgical resection + chemotherapy 1 (1/1)d
Outcome
Fetal 1/3
Patients treated survived 1/1
Patients not treated survived 0/2
Overall survival 1/3 = 33 %
Cases selected from the literature
a Tumor discovered before birth or on the first day of life
b Tumor discovered during the first 2 months of life
c Given for one patient only
d Combination chemotherapy using cisplatinum and vincristine. Patient
had a recurrence at age 10 months
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immunoreactive with GFAP, S-100, andβ-tubulin, suggesting
perhaps a mixed glial-neuronal phenotype [39]. Although his-
tologically SEGA resembles gemistocytic astrocytoma, the
latter is more infiltrative and located within the parenchyma
rather than a well-demarcated, exophytic intraventricular
growth. Moreover, SEGA cells tended to be larger than neo-
plastic gemistocytes, which also usually lack calcifications
[13, 73].
Treatment and outcome
Twelve of 18 SEGA patients were treated; 5 were not. One
nontreated neonate was lost to follow-up. Nine of 11 infants
treated with either surgical resection alone or surgery plus
evorolimus chemotherapy survived [40, 51, 56, 60, 64].
Overall survival rate was 70.6 % (Table 3). Fetal deaths were
five times greater than neonatal. Treatment of SEGA is
discussed in detail elsewhere [92].
Low-grade astrocytoma—pilocytic astrocytoma, grade I,
arises throughout the neural axis. The spinal cord, cerebral
hemisphere, and optic nerve were the tumor locations in this
review. Half occurred in the spinal cord [17, 53, 77], three in
the cerebral hemisphere [7, 44, 70, 83, 90], and two in the
optic nerve [7, 44] (Table 4). Intracranial mass on prenatal
imaging was the most common presentation in the fetus
whereas a spinal mass and paralysis were the main ones in
the neonate (Table 4).
Pathology
Low-grade 1 pilocytic astrocytoma exists on the benign end of
the histologic spectrum. The tumor consists of small bipolar
and stellate-shaped cells with scanty processes forming loose
and compact areas and microcysts [13, 39] (Fig. 3). Rosenthal
fibers and eosinophilic granular (cytoid) bodies are character-
istically but variably present. Anaplastic changes consisting of
cellular and nuclear pleomorphism, nuclear hyperchromatism,
neoplastic giant cells, and bizarre mitoses are absent. Mitoses
are uncommon. Astrocytoma cells react strongly with GFAP
and negatively with synaptophysin, neurofilament, desmin,
cytokeratin, and epithelial membrane antibodies [9, 13, 30,
39].
Optic pilocytic astrocytoma originates as a fusiform or
globular mass arising from the optic nerve [7, 9]. The tumor
produces a dumbbell-shaped mass with cyst formations in
both intraorbital and intracranial segments of the nerve.
There is a significant association between optic pathway
pilocytic astrocytoma and neurofibromatosis type 1
Table 9 Fetal and neonatal
astrocytoma: histological type,
grade versus survival (n = 101)
Tumor Grade Number Survival (%)
Glioblastoma IV 45 (44.6) 9/45 (20)
Subependymal giant cell astrocytoma I 18 (17.9) 11/18 (61)
Low-grade, I–II, astrocytoma I–II 10 (9.90) 9/10 (90)
Anaplastic astrocytoma III 10 (9.90) 6/10 (60)
Desmoplastic infantile astrocytoma/ganglioglioma I 10 (9.90) 8/10 (80)
Astroblastoma ?a 5 (4.90) 3/5 (60)
Gemistocytic astrocytoma II 3 (2.97) 1/3 (33.3)
Total 101 (100) 47/101 (46.5)
a Grade has not been assigned for this tumor (39,54)
Fig. 1 GBMs showing hypercellularity, marked pleomorphism, tumor
giant cells, microvascular proliferation, and Bpalisading necrosis^
(neoplastic spindle-shaped cells form palisades around central necrotic
foci)
Fig. 2 Microscopic examination revealing large astrocytic cells with
abundant pink staining cytoplasm, slightly vesicular nuclei, and
prominent nucleoli
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approaching 50 % in some series [9, 30, 34, 67]. This associ-
ation foretells a poor prognosis.
Treatment and outcome
All three patients with low-grade I and II cerebral astrocytoma
treated by surgical resection as the only form of therapy were
cured [70, 83, 90]. Both neonates with optic astrocytoma sur-
vived, one received surgery only and the other surgery plus
vincristine and carboplatin [7, 44]. There were five patients
with spinal cord tumors, and of these, four survived. Death
occurred in a 3120-g, 37-week gestation male fetus who was
the product of a breech presentation. He received a subtotal
resection for a spinal cord, T8–T11, tumor. Subsequently, the
baby developed paralysis of both upper and lower extremities
and died at age 8 weeks [17]. Overall survival for the entire
low-grade astrocytoma group was 9/10 or 90 %, which is the
highest figure recorded for the entire review (Tables 1, 2, 3, 4,
5, 6, 7, 8, and 9). Unfortunately, three of the four patients with
spinal cord tumors who survived had serious residual disabil-
ities. On the other hand, two with low-grade cerebral astrocy-
toma were left without significant ones. More detailed treat-
ment of low-grade astrocytoma is discussed elsewhere [16,
26, 65, 79].
Anaplastic astrocytoma occurs less often in older children
than the low-grade-astrocytoma whereas in the fetus and ne-
onate, the incidence of the two is about the same (Tables 4 and
5). The term Banaplastic astrocytoma^ refers to those tumors
of intermediate-grade malignancy corresponding to the WHO
classification grade III [13, 39].
Pathology
All ten anaplastic astrocytomas were located in the cerebral
hemispheres [14, 18, 19, 27, 57, 69, 80, 94] (Table 5).
Microscopically, they show cytoplasmic and nuclear pleomor-
phism, hypercellularity, mitotic activity to a degree, but lack
the pallisading necrosis or vascular proliferation of GBM [18,
19, 27, 69, 78, 80, 94] (Fig. 4). However, one exception was a
specimen from a stillborn fetus (therapeutic termination)
whose tumor was discovered by ultrasound at 31-week gesta-
tion; intracranial hemorrhage and vascular proliferation were
found along with pleomorphism, hypercellularity, and mitotic
activity, suggesting perhaps an early in utero transformation to
GBM [27]. GFAP and vimentin antibodies are reactive, but
NSE, synaptophysin, neurofilament, desmin, cytokeratin, and
epithelial membrane antigen are not.
Treatment and outcome
Six of ten patients with cerebral anaplastic astrocytomas were
treated by several modalities: (1) surgical resection as the only
form of therapy [18, 69], (2) surgery plus chemotherapy [19,
80, 94], and (3) surgery followed by chemotherapy and irra-
diation [78]. Five of six survived no matter what form of
therapy was given (Table 5). Of the four patients who were
not treated, one survived. Overall survival was 6/10 or 60 %.
Desmoplastic cerebral astrocytoma/desmoplastic cerebral
ganglioglioma of infancy (DIAGA) occurs most often during
the first year of life than at any other time [2, 4, 20, 25, 30, 45,
47, 62, 71, 81, 83, 86]. The diagnosis was made in this review
in nine neonates and in one fetus (Table 6). There was a 9:1
male predominance. Tumors in seven patients were detected
prenatally by ultrasound and appeared typically as a large
cystic mass with a solid component situated within a cerebral
hemisphere; most extended peripherally into the dura [20, 30,
45, 75, 86]. A large, intracranial hemorrhage was present also
in the fetal patient obscuring the tumor and making diagnosis
difficult [83].
An ongoing discussion in the literature exists regarding
nosology and grading of this group of tumors [30, 39]. The
question is raised whether infantile desmoplastic cerebral
ganglioglioma (DIAG) and desmoplastic cerebral astrocyto-
ma (DIA) represent the same histologic entity or two different
conditions. During the perinatal period, their clinical features,
pathology, treatment, and outcome are almost the same.
In addition, there is some disagreement about the WHO
grading classification [30, 39]. The initial benign histology
Fig. 3 The tumor consisting of small bipolar and stellate-shaped cells
with scanty processes forming loose and compact areas and microcysts
Fig. 4 Anaplastic astrocytomas showing cytoplasmic and nuclear
pleomorphism, hypercellularity, mitotic activity to a degree, but lack the
pallisading necrosis or vascular proliferation of GBM
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and clinical findings in the ten patients in this review are more
consistent with a grade I–II tumor rather than a high-grade
one. Nevertheless, it should be mentioned that some
DIAGAs reported in some older children and adults have been
diagnosed malignant [2, 62].
Pathology
Characteristic histologic findings are a cellular, spindle cell
tumor with a prominent collagenous (Bdesmoplastic,^ fibrous)
stroma composed of bipolar and spindle-shaped cells having
an eosinophilic cytoplasm and cells with long processes [20,
30, 45, 83, 86] (Fig. 5). Astrocytic cells form bundles and
nests separated by thick bands of collagen [4, 30, 45, 83,
86]. Lymphocytes are variably present. Reticulin stain shows
thick fibers surrounding nests of individual cells. Tumor cells
and their processes react with GFAP and collagen fibers stain
strongly blue with Masson’s trichrome [20, 30]. Ganglion
cells were present in the six DIAG tumors but not identified
in the four DIAs (Table 6).
Treatment and outcome
Eight of ten patients who were treated by surgery alone were
cured [2, 4, 25, 47, 81, 88]. The male fetus listed in Table 6
was operated upon at age 2 months for removal of a DIAG.
Eight years later, he died; the tumor recurred as GBM [62].
DIAGA is one of the astrocytoma groups usually associated
with a relatively good prognosis overall provided that a com-
plete resection was done; there was an 80 % survival for this
group of tumors [4, 20, 45, 86] (Table 6).
Astroblastoma is a rare, controversial, supratentorial, tumor
first described by Bailey and Bucy in 1930 [3]. The existence
of this neoplasm has been debated ever since. The exact cell of
origin has not been established [61]. Currently, it is placed in
theWHO classification as a neuroepithelial tumor of uncertain
origin [39]. It is exceedingly rare for less than five prenatal
cases have been reported [5, 29, 35, 61, 66, 87] (Table 7).
Pathology
The dominant histologic feature is the characteristic
perivascular pseudorosette [8, 66]. Two definite histolog-
ical types of astroblastoma are described: low-grade and
high-grade [8]. The low-grade lesion is a better differen-
tiated tumor with more benign histologic findings, and
the high-grade type has more anaplastic features and a
poorer prognosis [8]. Low-grade astroblastoma consists
of orderly perivascular pseudorosettes, having a papillary
appearance, minimal cellular atypia, rare mitoses, and no
microvascular proliferation. High-grade lesions show loss
of the typical papillary architecture, areas of solid
growth, increased cellularity with nuclear atypia, in-
creased mitotic activity, and microvascular proliferation
[8, 52, 85]. As one would anticipate low-grade, differen-
tiating astroblastoma has a better prognosis than the an-
aplastic type [52]. At present, a WHO grade has not been
assigned to this tumor [52].
The main entity in the differential diagnosis of
astroblastoma is the well-differentiated ependymoma [13,
61, 66] . Clear spaces are present be tween the
astroblastoma pseudorosettes whereas the ependymoma
has a more compact architecture. There are differences
in nuclear characteristics and thickness of the perivascular
cytoplasmic processes as well. Astroblastomas exhibit
broad foot plates opposed to tapering processes as seen
in ependymomas [61]. Some tumors may resemble papil-
lary meningioma or even a choroid plexus tumor. The
main difference here is that astroblastoma is immunoreac-
tive with GFAP whereas the meningioma is not; choroid
plexus papilloma is focally GFAP positive [13].
Treatment and outcome
Treatment of astroblastoma is unsettled, largely because the
rarity of the tumor precludes definitive therapeutic studies.
Anaplastic histology is an important prognostic factor.
Surgical resection is regarded as the preferred treatment mo-
dality; it plays a major role in managing the well-differentiated
astroblastoma [52]. The precise role for irradiation and che-
motherapy has not been well defined since only a few cases
have been published to date [85]. However, these procedures
could be considered in the treatment of the anaplastic type
[52]. Prognosis is further complicated by the potential of the
astroblastoma converting a more malignant form of glioma,
namely GBM [8]. The clinical course is unpredictable.
Gemistocytic astrocytoma (GA) is a member of the diffuse
astrocytoma group [13, 39, 41, 54]. It is much more common
Fig. 5 Characteristic histologic findings showing a cellular, spindle cell
tumor with a prominent collagenous (desmoplastic, fibrous) stroma
composed of bipolar and spindle-shaped cells having an eosinophilic
cytoplasm and cells with long processes. The prominent, blue collagen
component is shown by the Mallory trichrome stain.
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in older individuals where survival rates are higher than those
in the fetus and neonate. Literature review uncovered only
three examples of fetal GA all detected by prenatal ultrasound
[6, 48, 54] (Table 8).
Pathology
Certain histologic criteria are required to make the diagno-
sis of GA. The main one is that a significant number of
neoplastic gemistocytic astrocytes must be present in the
tumor, at least 20 %, since collect ions of well-
differentiated GA cells can mimic reactive astrocytes
[39]. Although the tumor resembles SEGA, the GA cells
are smaller and have a more prominent, eosinophilic cyto-
plasm containing an eccentric nucleus and a small nucleo-
lus. Cells are surrounded by thick and thin cell processes.
Tumor cells are reactive with GFAP and vimentin, either
diffusely or focally [6, 48, 54]. There is a second atypical
cellular component consisting of smaller cells with prom-
inent, more darkly staining nuclei and scant, sometimes
barely visible cytoplasm. This is the so-called growth
(proliferative) fraction which is MIB-1/Ki67 reactive [13,
39]. The larger eosinophilic cells show a much lower pro-
liferation rate than the smaller component. Perivascular
lymphocyte cuffing is variably present to some degree.
All three GA patients in this review had large hemispheric
tumors detected by prenatal ultrasound or on the day of birth.
The first patient in Table 8, a female of 32-week gestation,
died at 2 months of age without treatment [6]. The GA occu-
pied half of the intracranial cavity. Her histology showed no
necrosis, vascular proliferation, or other cellular atypical fea-
tures [6]. The second patient received surgery and chemother-
apy and survived [54]. The third infant lived for 6 days with-
out treatment. Her tumor cells exhibited mild pleomorphism,
increased cellularity, a low MIB-1 index (<1 %), but palisad-
ing necrosis and endothelial proliferation were noted; this tu-
mor was designated as malignant [48].
Treatment and outcome
The only survivor, patient 2 (tumorWHO grade 2), was a full-
term male with a right occipital lobe primary [54] (Table 8).
Microscopically, the GA revealed atypical tumor cells and an
elevated MIB-1 index of 15 %. The child was alive and well
even after a relapse at age 2.5 years. He was treated by com-
plete surgical resection and chemotherapy consisting of vin-
cristine and cis-platinum [54]. Current therapy of GA is
discussed elsewhere [22, 26, 28, 65].
GA shows a tendency to behave aggressively more than
other grade I and II astrocytomas. Some may progress to an-
aplastic astrocytoma and eventually GBM [54].
Discussion
Astrocytoma is the foremost neuroglial tumor occurring
throughout infancy and childhood and is derived from and
composed of astrocytes showing varying degrees of differen-
tiation. As a group, astrocytomas differ in their gross and
histological features as well as in their site of origin and clin-
ical manifestations [12, 15, 27, 30, 31, 37, 57, 68, 93]
(Table 9).
Most perinatal astrocytomas occur outside the posterior
cranial fossa and above the tentorium (Tables 2). When it
can be determined, the cerebral hemisphere is the most com-
mon primary site. Those arising from this location tend to be
large, involve more than one lobe, and displace the ventri-
cle(s). In some instances, the brain may be almost completely
replaced by tumor.
Astrocytoma typically presents in the fetus and neonate as
an intracranial mass, which is the initial observation on pre-
natal or postnatal sonograms; hydrocephalus macrocephaly
and intracranial hemorrhage, in that order, are additional pre-
senting findings (Tables 2, 3, 4, 5, 6, 7, and 8).
Tumors vary considerably in their microscopic appearance.
Histologically, they range from benign (low-grade) to malig-
nant (high-grade) tumors (Table 9). Here, there were 55 high-
grade astrocytomas compared to 46 low-grade ones [52].
Treatment is primarily surgical, like other brain tumors in
this age group [31]. Sometimes surgery is preceded by a shunt,
and in selected cases followed by chemotherapy [30, 31, 37].
Usually, irradiation is contraindicated because of immaturity
of the developing brain and adjacent structures. The extent
and size of the tumor and the general condition of the neonate
are limiting factors that can preclude surgery. Some tumors
can be inoperable because of their large size or unstable con-
dition of the infant [31].
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